Hollencrest Capital Management Makes New Investment in ADMA Biologics, Inc. (NASDAQ:ADMA)

Hollencrest Capital Management bought a new stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 1,506 shares of the biotechnology company’s stock, valued at approximately $30,000.

Other hedge funds have also recently modified their holdings of the company. D. E. Shaw & Co. Inc. boosted its holdings in ADMA Biologics by 26.8% during the 2nd quarter. D. E. Shaw & Co. Inc. now owns 6,824,517 shares of the biotechnology company’s stock valued at $76,298,000 after acquiring an additional 1,442,799 shares during the period. Assenagon Asset Management S.A. boosted its stake in shares of ADMA Biologics by 2.7% during the third quarter. Assenagon Asset Management S.A. now owns 3,474,455 shares of the biotechnology company’s stock valued at $69,454,000 after purchasing an additional 92,281 shares during the period. Driehaus Capital Management LLC grew its holdings in shares of ADMA Biologics by 17.3% in the second quarter. Driehaus Capital Management LLC now owns 3,028,667 shares of the biotechnology company’s stock worth $33,860,000 after purchasing an additional 447,743 shares during the last quarter. Renaissance Technologies LLC increased its stake in ADMA Biologics by 28.7% in the 2nd quarter. Renaissance Technologies LLC now owns 2,582,135 shares of the biotechnology company’s stock worth $28,868,000 after buying an additional 575,100 shares during the period. Finally, Federated Hermes Inc. lifted its holdings in ADMA Biologics by 15.5% during the 2nd quarter. Federated Hermes Inc. now owns 1,969,811 shares of the biotechnology company’s stock valued at $22,022,000 after buying an additional 263,677 shares in the last quarter. Institutional investors own 75.68% of the company’s stock.

ADMA Biologics Price Performance

Shares of ADMA opened at $22.62 on Friday. The company has a debt-to-equity ratio of 0.74, a quick ratio of 2.80 and a current ratio of 6.87. The company has a 50 day moving average price of $18.12 and a 200-day moving average price of $13.89. ADMA Biologics, Inc. has a fifty-two week low of $3.60 and a fifty-two week high of $23.52. The stock has a market capitalization of $5.27 billion, a PE ratio of 161.57 and a beta of 0.64.

ADMA Biologics (NASDAQ:ADMA) last posted its earnings results on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share for the quarter, topping analysts’ consensus estimates of $0.08 by $0.05. ADMA Biologics had a return on equity of 38.79% and a net margin of 10.53%. The company had revenue of $107.20 million during the quarter, compared to analyst estimates of $86.44 million. During the same quarter in the prior year, the business earned ($0.02) earnings per share. ADMA Biologics’s revenue was up 78.4% on a year-over-year basis. Equities analysts predict that ADMA Biologics, Inc. will post 0.49 earnings per share for the current fiscal year.

Analyst Ratings Changes

ADMA has been the topic of a number of research analyst reports. Cantor Fitzgerald restated an “overweight” rating and issued a $20.00 target price on shares of ADMA Biologics in a research note on Friday, September 20th. HC Wainwright raised their price objective on ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a report on Friday. Finally, Raymond James lifted their target price on ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a research report on Friday. One investment analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $21.25.

Insider Transactions at ADMA Biologics

In other ADMA Biologics news, Director Lawrence P. Guiheen sold 9,000 shares of ADMA Biologics stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $18.47, for a total value of $166,230.00. Following the transaction, the director now owns 153,941 shares in the company, valued at $2,843,290.27. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other ADMA Biologics news, Director Lawrence P. Guiheen sold 9,000 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $18.47, for a total value of $166,230.00. Following the completion of the sale, the director now directly owns 153,941 shares in the company, valued at $2,843,290.27. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Adam S. Grossman sold 236,889 shares of ADMA Biologics stock in a transaction on Monday, August 26th. The stock was sold at an average price of $17.69, for a total transaction of $4,190,566.41. Following the completion of the transaction, the chief executive officer now directly owns 2,059,726 shares in the company, valued at $36,436,552.94. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 466,900 shares of company stock valued at $8,224,121. Corporate insiders own 3.70% of the company’s stock.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.